Medicament and method for treating innate immune response diseases

Patent metadata

Field	Value
Publication number	US-2016346364-A1
Application number	US-201415101630-A
Country	US
Kind code	A1
Filing date	Dec 11, 2014
Priority date	Dec 11, 2013
Publication date	Dec 1, 2016
Grant date	—

Abstract

This invention relates to a medicament or a dietary supplement comprising the Aspergillus niger aspergilloglutamic peptidase that is capable of hydrolyzing plant food allergens, and more particularly, alpha-amylase/trypsin inhibitors, thereby treating diseases due to an innate immune response in humans, and/or allowing to delay the onset of said diseases. The present invention relates to the discovery that the Aspergillus niger aspergilloglutamic peptidase is capable of hydrolyzing alpha-amylase/trypsin inhibitors that are present in wheat and related cereals said inhibitors being strong inducers of innate immune response. Furthermore, the present invention relates to a method for hydrolyzing alpha-amylase/trypsin inhibitors comprising incubating a composition for food consumption comprising alpha-amylase/trypsin inhibitors with the Aspergillus niger aspergilloglutamic peptidase, wherein the inhibitors are hydrolyzed. It also relates to an enzyme composition comprising the Aspergillus niger aspergilloglutamic peptidase and an additional enzyme, and to foodstuff comprising the Aspergillus niger aspergilloglutamic peptidase.

First claim

1 . A dietary supplement or a pharmaceutical composition comprising the Aspergillus niger aspergilloglutamic peptidase, a prolyl-endopeptidase, and pharmaceutically or dietary acceptable excipients.

2 . A dietary supplement or a pharmaceutical composition according to claim 1 , further comprising an aspergillopepsin I.

3 . A dietary supplement or a pharmaceutical composition according to claim 1 , wherein the supplement is in the form of a tablet, capsule or a liquid formulation.

4 . A dietary supplement or a pharmaceutical composition comprising the Aspergillus niger aspergilloglutamic peptidase for use as a medicament.

5 . Use according to claim 4 , wherein the composition further comprises a prolyl-endopeptidase, and pharmaceutically or dietary acceptable excipients.

6 . Use according to claim 4 , wherein the composition further comprises an aspergillopepsin I.

7 . Use according to claim 4 , wherein the medicament is for the treatment of a patient suffering from innate immune response in the intestine.

8 . Use according to claim 4 , wherein the medicament is for the treatment of celiac disease, non-celiac gluten intolerance, gluten sensitivity, irritable bowel syndrome, or inflammatory bowel disease.

9 . Use according to claim 4 , wherein the medicament is a dietary supplement for maintaining or enhancing gastrointestinal comfort in gluten sensitive individuals, or for delaying the onset of gastrointestinal discomfort in celiac or non-celiac gluten sensitive individuals, as well as for decreasing alpha-amylase/trypsin inhibitor exposure in healthy individuals.

10 . Use according to claim 4 , wherein the medicament is administered orally within 1 hour prior or after a meal.

11 . Method for degrading plant allergens in a food composition comprising, incubating a food composition containing plant allergens with Aspergillus niger aspergilloglutamic peptidase, for a time sufficient to hydrolyze plant allergens.

12 . A foodstuff prepared by first incubating a food product containing plant allergens with Aspergillus niger aspergilloglutamic peptidase, for a time sufficient to hydrolyze plant allergens, said foodstuff comprising degraded alpha-amylase/trypsin inhibitors.

13 . A baking composition or a dough comprising the Aspergillus niger aspergilloglutamic peptidase, and a prolyl-endopeptidase.

14 . A method to prepare a dough comprising the step of adding an Aspergillus niger aspergilloglutamic peptidase to at least one dough ingredient.

15 . An enzyme composition comprising the Aspergillus niger aspergilloglutamic peptidase and at least one additional enzyme.

Assignees

• Dsm Ip Assets Bv

Inventors

• Bruins Maaike Johanna
• Edens Luppo
• Nan Lenneke

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• C12C5/004

  Enzymes · CPC title